RAPT Therapeutics Inc (NASDAQ: RAPT) kicked off on Monday, up 3.70% from the previous trading day, before settling in for the closing price of $1.08. Over the past 52 weeks, RAPT has traded in a range of $1.00-$27.35.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -36.87% over the past five years. While this was happening, its average annual earnings per share was recorded 18.86%. With a float of $30.56 million, this company’s outstanding shares have now reached $34.40 million.
Let’s look at the performance matrix of the company that is accounted for 131 employees. In terms of profitability, gross margin is 82.19%, operating margin of -2171.96%, and the pretax margin is -2032.75%.
RAPT Therapeutics Inc (RAPT) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of RAPT Therapeutics Inc is 12.58%, while institutional ownership is 75.02%. The most recent insider transaction that took place on Jan 05 ’24, was worth 20,456. In this transaction CHIEF SCIENTIFIC OFFICER of this company sold 898 shares at a rate of $22.78, taking the stock ownership to the 27,820 shares. Before that another transaction happened on Dec 21 ’23, when Company’s Chief Medical Officer sold 2,500 for $21.68, making the entire transaction worth $54,200. This insider now owns 15,020 shares in total.
RAPT Therapeutics Inc (RAPT) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.81 earnings per share (EPS), higher than consensus estimate (set at -0.87) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.86% per share during the next fiscal year.
RAPT Therapeutics Inc (NASDAQ: RAPT) Trading Performance Indicators
Take a look at RAPT Therapeutics Inc’s (RAPT) current performance indicators. Last quarter, stock had a quick ratio of 9.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.78, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of RAPT Therapeutics Inc (RAPT)
RAPT Therapeutics Inc (NASDAQ: RAPT) saw its 5-day average volume 0.61 million, a negative change from its year-to-date volume of 0.76 million. As of the previous 9 days, the stock’s Stochastic %D was 9.02%. Additionally, its Average True Range was 0.28.
During the past 100 days, RAPT Therapeutics Inc’s (RAPT) raw stochastic average was set at 4.25%, which indicates a significant decrease from 5.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 236.61% in the past 14 days, which was higher than the 127.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8280, while its 200-day Moving Average is $4.8498. Nevertheless, the first resistance level for the watch stands at $1.1767 in the near term. At $1.2333, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2667. If the price goes on to break the first support level at $1.0867, it is likely to go to the next support level at $1.0533. The third support level lies at $0.9967 if the price breaches the second support level.
RAPT Therapeutics Inc (NASDAQ: RAPT) Key Stats
The company with the Market Capitalisation of 40.27 million has total of 34,958K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -116,800 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -18,430 K.
